Contrast Enhanced Ultrasound Market Analysis

  • Report ID: 5642
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Contrast Enhanced Ultrasound Market Analysis

Type (Microbubble Contrast Agents, Phase-Change Contrast Agents)

In terms of type, the microbubble contrast agents segment is estimated to gain the largest contrast-enhanced ultrasound market share of 60% in the year 2037. The microbubble contrast agent segment growth can be accounted for on the back of increasing cases of liver-related diseases including cirrhosis and hepatocellular carcinoma.

Liver diseases often require precise imaging for accurate diagnosis and monitoring of lesions, and microbubble contrast agents enhance the visibility of vascular structures and lesions during ultrasound imaging. Around a 25% rise has been recorded annually in the incidence of hepatocellular carcinoma globally in the last decade, reported as per a study.

This rapid growth in liver diseases underscores the critical need for advanced imaging techniques, such as contrast-enhanced ultrasound with microbubble contrast agents, for effective diagnosis and management. Continuous advancements in ultrasound technology, including improvements in transducer design and image processing algorithms, are driving the growth of the microbubble contrast agents segment.

End Users (Hospitals, Diagnostic Imaging Centers, Research and Academic Institutions)

Based on end users, the hospital segment is expected to garner the highest CAGR of 50% during the projected timeframe. Hospitals serve as primary centers for diagnosing and managing liver diseases, and the demand for CEUS in this segment is driven by the need for accurate and non-invasive imaging to assess liver lesions.

The hospital segment growth is assessed to rise due to increasing cardiovascular disease cases recorded globally. Hospitals play a central role in cardiovascular care, and the utilization of CEUS for cardiac imaging contributes to the comprehensive assessment of patients with conditions such as myocardial infarction, heart failure, and valvular disorders.

Our in-depth analysis of the global market includes the following segments:

 

            Type

  • Microbubble Contrast Agents
  • Phase-Change Contrast Agents

            End User

  • Hospitals
  • Diagnostic Imaging Centers
  • Research and Academic Institutions

            Technology

  • Targeted
  • Non-targeted
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5642
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of contrast-enhanced ultrasound is estimated at USD 1.96 billion.

The contrast-enhanced ultrasound market size was over USD 1.87 billion in 2024 and is anticipated to cross USD 3.94 billion by 2037, growing at more than 5.9% CAGR during the forecast period i.e., between 2025-2037. The market growth is driven by increase in R&D activities, collaboration, product approvals, and launches.

North America industry is estimated to dominate majority revenue share of 33% by 2037, due to rising technological advancement in medical imaging in the region.

The major players in the market include General Electric Company, Siemens Healthineers, Philips Healthcare, Lantheus Holdings, Inc., Bracco Diagnostic, GE HealthCare, CANON MEDICAL SYSTEMS CORPORATION, Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample